One-time administration maintains efficacy for 6 months long-acting rhinosinusitis innovative therapy clinical results are positive

On June 30, 2021, Lyra Therapeutics announced that its main product candidate LYR-210 has obtained positive pharmacokinetic (PK) results in clinical trials for the treatment of chronic sinusitis (CRS)

Lyra was co-founded by Professor Robert Langer, a well-known scholar from the Massachusetts Institute of Technology (MIT)

The main symptoms of patients with chronic sinusitis include nasal congestion, facial pain and pressure, nasal discharge, and hyposmia

LYR-210 is a non-invasive alternative to sinus surgery, which can directly act on inflamed mucosal tissues

▲LYR-210 can directly act on the inflamed mucosa and provide anti-inflammatory treatment for up to 6 months (picture source: Lyra's official website and reference materials [2])

This open-label, multi-center pharmacokinetic trial enrolled 24 adult patients with chronic sinusitis, and aimed to evaluate the pharmacokinetics and safety of LYR-210

Previously, in the 6-month phase 2 clinical trial of LANTERN, 7500 µg LYR-210 was shown to provide rapid, lasting, and clinically significant symptom improvement in patients with chronic sinusitis

Note: The original text has been deleted

Reference materials:

[1] Lyra Therapeutics Announces Positive Topline Results Of Pharmacokinetic Study Of Lyr-210 In Patients With Chronic Rhinosinusitis.

[2] Lyra Lantern Phase 2 Study Results For Lyr-210 In Crs.

[3] Lyra Therapeutics and Liantuo Biotech announced that they have reached a strategic cooperation and exclusive license agreement to jointly develop and commercialize LYR-210 in the Greater China region and other Asian markets.